The large TESTS sepsis trial did not demonstrate a mortality benefit. Its result and linked correction belong in any account of that indication.
This is not a determination that every indication is ineffective or that all jurisdictions share an approval status. Each claim needs its own study and product context.
Sources and proposed-mechanism explanation
Immune signaling is context dependent. “Boosting immunity” is too imprecise to describe a measurable clinical benefit.